Navigation Links
Gamida Cell Announces $4.4 Million Grant from the Israeli Government
Date:5/23/2016

JERUSALEM, May 23, 2016 /PRNewswire/ --

Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today it has been awarded a grant of up to $4.4 million from the Israel Innovation Authority (formerly the Office of the Chief Scientist) of the Israeli Ministry of Economy and Industry. The mission of the Israel Innovation Authority is to encourage innovation and entrepreneurship in various industries, including science and technology, while stimulating economic growth.

The non-dilutive funding will support Gamida Cell's ongoing research and development efforts including its Phase 3 registration study of NiCord® for hematological malignancies (blood cancers like leukemia and lymphoma), and its clinical trials of CordIn® for sickle cell disease and thalassemia and NK cells as a potential immune therapy for cancer.

"We are very pleased to have received this grant and know it will contribute to our broad clinical development plans for this year, which include the launch of a registration study for our lead program and early clinical stage work on our immuno-oncology candidate. The grant announced today is the largest amount we have been rewarded to date. We feel it is a clear demonstration of the Innovation Authority's ongoing confidence and trust in our important mission," said Dr. Yael Margolin, Gamida Cell's president and CEO.

About Gamida Cell  

Gamida Cell is a world leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company's pipeline of products are in development to treat a wide range of conditions including cancer, genetic hematological diseases such as sickle cell disease and thalassemia, bone marrow failure syndromes such as aplastic anemia, genetic metabolic diseases and refractory autoimmune diseases. Gamida Cell's current shareholders include: Novartis, Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharmaceutical Industries, Denali Ventures and Auriga Ventures.   For more information please visit http://www.gamida-cell.com.

Press Contact:
Marjie Hadad
MH Communications
+972-54-536-5220
marjierhadad@gmail.com

Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
+1-212-362-1200
beth@sternir.com


'/>"/>
SOURCE Gamida Cell
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Elbit Imaging Announces Gamida Cell Closed Option and Investment Agreements with a Major Pharmaceutical Company
2. Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company
3. Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
4. Purdue Pharma Announces Patent Agreement with Egalet and Acura
5. DS Biopharma Announces DS102 will be Developed for Pulmonary Disorders in Addition to NASH
6. Mauna Kea Technologies Announces Strong Presence of Cellvizio Platform at Major Medical Meetings Focused on Gastroenterology
7. Global Blood Therapeutics Announces Presentation of New GBT440 Data in Sickle Cell Disease at the European Hematology Associations 21st Congress
8. Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
9. Lightpoint Medical Announces Exclusive Global License Agreement With the University of Arizona to Develop Molecular Imaging Technology
10. New Colombia Resources Sannabis Subsidiary Announces Filing for Medical Marijuana Licenses With the Ministry of Justice in order to Export Products
11. Aptuit Announces Acquisition of Kuecept Ltd
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2019)... ... December 06, 2019 , ... ... of treatments for psychiatric and neurodegenerative disorders, announced today that the U.S. Food ... NBTX-001 Inhaler, allowing the Company to initiate its Phase 2b trial for the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... entrance into the Amazon Web Services (AWS) Public Sector Partner Program; a ... Public Sector Partner program recognizes and collaborates with partners that offer solutions ...
(Date:12/4/2019)... ... December 04, 2019 , ... Tenex ... minimally invasive technologies to treat chronic pain in soft and hard tissue, recently ... TX® technology. , Dr. Bernard Morrey, Chief Medical Officer of Tenex ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... December 06, 2019 , ... Allegheny Health Network (AHN) has named ... joined AHN from WVU Medicine in May 2018, previously served as AHN’s Vice Chair ... interim chair since October and is also part of the pathology faculty at Drexel ...
(Date:12/6/2019)... ... December 06, 2019 , ... Dr. Scott Howell, a 2019 graduate of Trident ... the health benefits of coconut oil in the 7 November 2019 edition of ... Cardiometabolic Profile: A Structured Literature Review,” led by Dr. Hector O. Santos, examines the ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... ranging from launching exceptional products that help people embrace, achieve, and maintain a ... “We’ve never been more committed to our mission of impacting world health, so ...
(Date:12/4/2019)... ... December 04, 2019 , ... Healthcare Real ... the only national awards dedicated to recognizing excellence in the areas of healthcare ... presented in nine different categories during the GlobeSt Healthcare Conference today in Scottsdale, ...
(Date:12/2/2019)... ... December 02, 2019 , ... TrialScope, the global leader ... the North American branch of the healthcare business of Merck KGaA, Darmstadt, Germany, ... educate and inform patients, caregivers, the public, patient advocacy groups and healthcare professionals ...
Breaking Medicine News(10 mins):